|Daily Range||$1.10 - $1.16|
|52-Week Range||$0.94 - $4.82|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||1,745,642|
|Current FY EPS||-$0.59|
Treatments with huge promise don't always pan out the way you'd expect.
Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.